title: Use of the levonorgestrel releasing-intrauterine system in nulliparous women--a non-interventional study in Sweden.
abstract: OBJECTIVE
  To evaluate the insertion procedure and continuation rates of the levonorgestrel releasing-intrauterine system (LNG-IUS) in nulliparous women who, due to fear of complications, are often denied this very effective contraceptive method.
  
  
  METHODS
  A non-interventional study of 224 nulliparous women attending family planning services for insertion of a LNG-IUS.
  
  
  RESULTS
  There were only six unsuccessful insertions. The insertions, mostly carried out by midwives, were regarded as easy by 72% of the inserters. Nineteen women (9%) considered the procedure to have been painless, 162 (72%) moderately painful, and 39 (17%), severely painful. At follow-up, 12-16 weeks post-insertion, 76% (165/216) of the women were satisfied with their method. Women in the youngest age group were more satisfied than women in the oldest age group (75% and 59%, respectively). Only 5% were dissatisfied. Neither perforations nor pregnancies were reported during the whole study period.
  
  
  CONCLUSIONS
  Our results support the current practice in Sweden of offering LNG-IUS routinely to nulliparous women.
authors.affiliation: Department of Obstetrics and Gynaecology, Division of Women's and Children's Health, Karolinska University Hospital/Institutet, Stockholm, Sweden. lena.marions@ki.se
authors.forename: Lena
authors.initials: L
authors.lastname: Marions
authors.forename: Lena
authors.initials: L
authors.lastname: Lövkvist
authors.forename: Annika
authors.initials: A
authors.lastname: Taube
authors.forename: Monica
authors.initials: M
authors.lastname: Johansson
authors.forename: Håkan
authors.initials: H
authors.lastname: Dalvik
authors.forename: Inger
authors.initials: I
authors.lastname: Øverlie
mesh_terms: D000282:Administration, Intravaginal; D000328:Adult; D003267:Contraception / Q000009:adverse effects / Q000706:statistics & numerical data*; D003271:Contraceptive Agents, Female / Q000008:administration & dosage* / Q000009:adverse effects; D016503:Drug Delivery Systems / Q000009:adverse effects / Q000706:statistics & numerical data*; D005260:Female; D006801:Humans; D007436:Intrauterine Devices, Medicated / Q000009:adverse effects / Q000706:statistics & numerical data*; D016912:Levonorgestrel / Q000008:administration & dosage* / Q000009:adverse effects; D008875:Middle Aged; D010298:Parity; D017060:Patient Satisfaction; D045167:Progesterone Congeners / Q000008:administration & dosage* / Q000009:adverse effects; D013548:Sweden / Q000453:epidemiology; D055815:Young Adult
chemical_list: D003271:Contraceptive Agents, Female; D045167:Progesterone Congeners; D016912:Levonorgestrel